Detalhe da pesquisa
1.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Lancet Oncol
; 23(3): 416-427, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35151415
2.
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.
Haematologica
; 107(6): 1397-1409, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34647444
3.
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Leukemia
; 35(2): 562-572, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32444867